Here with David Gandara , ISLB CMO, and some amazing members of the ISLB Young Committee! 🙌 Great to meet in person and share ideas 💡on how to keep growing together. Excited for what’s ahead! the best is yet to come! #ASCO25 @Booth12041 Carolina Reduzzi Mohamed A Gouda

OS results from #INAVO120 at #ASCO25 confirm the benefit of inavolisib in PIK3CA-mut HR+/HER2- #MBC ➖PFS: 17.2 vs 7.3 mo (HR 0.42) ➖ OS: 34.0 vs 27.0 mo (HR 0.67, p=0.019) ➖ ORR: 62.7% vs 28.0% ⚠️ Biomarkers move to the 1L decision making 🔭 future PI3Ki ➡️ AKT1 sequencing?

Ipatasertib shows significant PFS impact in HR+/HER2- #MBC post-CDK4/6i 👥 ITT: mPFS 5.3 vs 1.9 m HR 0.61 (p=0.0007) 🧬 AKT/PTEN/PIK3CA-altered subgroup: mPFS 5.45 vs 1.91 m HR 0.47 (p=0.0005) Although no interaction, benefit seems driven by the biomarker population #ASCO25

DESTINYBreast06 at #ASCO25 suggests a greater benefit from T-DXd in BRCA1/2-mutant #MBC (HR 0.17) ‼️Small N (20 pts) 🧬 biologically plausible synergy via DNA damage. ⚠️ Still no data on key biomarkers like ERBB2 #BreastCancer #ADC #Biomarkers #PrecisionMedicine

If you are a young researcher with an interest in liquid biopsy, come talk to us at the International Society of Liquid Biopsy booth at #ASCO2025 about the activities of the Young Committee and how to join! Roberto patricio

SERENA6 at #ASCO25: A crucial step for clinical utility of #liquidbiopsy ⏱️ Switching to camizestrant + CDK4/6i upon pre-progression detection of #ESR1 mut in #ctDNA improved PFS1(16.0 vs 9.2 mo; HR 0.44). 🧪 PFS2 showed a promising early signal (HR 0.52) although not mature

DESTINY-B09 at #ASCO25: ✅ T-DXd + P improved PFS vs THP (40.7 vs 26.9 mo; HR 0.56) 🔭 Benefit consistent across subgroups, incl. PIK3CA mut/wt #MBC ⏱️ ORR 85% with durable responses ⏳ ~16–20% maturity for OS/PFS2 – further follow-up awaited Is there room for maintenance?

Couldn’t make it to the packed #ASCO25 session? Join GRASP next week for a small-group discussion on the #DESTINYBreast09 practice-changing data showing Enhertu's potential in earlier-line HER2+ MBC. Register at tinyurl.com/27c83p3v #bcsm

Join UNC's Assistant Professor of Medicine Yara Abdou, MD, MSCR on June 12 as she discusses racial inequities and HER2-Negative breast cancer. This group will fill up fast, so make sure you register today graspcancer.org/events/asco25-… #asco2025 #bcsm #registertoday #GRASPPosters #GRASPatASCO

Join Mentor Janice Cowden on Wednesday, June 12 at 2:00 pm as she leads the discussion on Triple-Negative Breast Cancer and Antibody-Drug Conjugates (ACDs). These sessions fill up fast, so register today! graspcancer.org/events/asco25-… #asco #asco2025 #bcsm #registertoday

Really grateful for another successful #YBO event in beautiful #genova…definitely a bright future ahead for 🇮🇹 with such an excellent and motivated young #BreastCancer community ❤️🤩🔝💪 Università di Genova Ospedale San Martino Genova Luca Arecco, MD OncoAlert

Join GRASP Scientist Jennifer Sheng, M.D., as we discuss alcohol intake and health-related quality of life in breast cancer survivors, and alcohol intake. Join us on June 11 for a deeper into these topics and discuss Posters. graspcancer.org/events/asco25-… #bcsm #GRASPPosters #alcohol

It’s an honor and an incredible opportunity to be part of this project! Looking forward to diving into #liquidbiopsy and treatment resistance in ER+/HER2- metastatic #breastcancer. 📅 June 11, 2:00pm EDT Join us! 👇 #ASCO25 #bcsm #GRASPPosters #GRASPatASCO #MBC #ctDNA

📢 Just out on @CROH our Italian Delphi consensus 🤝🏻on the evolving landscape of HR+/HER2- mBC (EVOLVE). 💊Resistance/sensitivity to CDK4/6i+ET 🧬Biomarkers 🔎Treatment algorithm 📃: doi.org/10.1016/j.crit… Proud to be part of this huge national effort.

Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬 👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC. doi.org/10.1016/j.tran…

Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER) buff.ly/UrXfLEu In this open-label, phase II trial of pretreated HER2-positive advanced #BreastCancer , trastuzumab plus

Mark your calendar for the International Inflammatory Breast Cancer Symposium! 🗓️ October 23, 2025 📍 Milan (Italy) 🌐 Join in person or online Don’t miss this opportunity to connect with global IBC experts, share ideas, and advance research to improve patient outcomes.